MarketAxess (MKTX) to Release Earnings on Wednesday

Share on StockTwits

MarketAxess (NASDAQ:MKTX) is scheduled to be releasing its earnings data before the market opens on Wednesday, July 24th. Analysts expect MarketAxess to post earnings of $1.27 per share for the quarter.

MarketAxess (NASDAQ:MKTX) last posted its quarterly earnings results on Wednesday, April 24th. The financial services provider reported $1.39 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.37 by $0.02. The company had revenue of $124.49 million for the quarter, compared to the consensus estimate of $125.43 million. MarketAxess had a return on equity of 29.88% and a net margin of 39.84%. The firm’s quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.27 EPS. On average, analysts expect MarketAxess to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

MKTX stock opened at $370.48 on Tuesday. The firm has a market cap of $13.84 billion, a P/E ratio of 81.07, a P/E/G ratio of 14.11 and a beta of 0.22. MarketAxess has a twelve month low of $172.09 and a twelve month high of $373.98. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.82 and a current ratio of 10.82. The company has a fifty day moving average of $336.42.

Several analysts recently commented on the company. Buckingham Research dropped their price objective on State Street from $83.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, June 12th. Rosenblatt Securities assumed coverage on Tradeweb Markets in a research note on Monday, April 15th. They set a “buy” rating and a $45.00 price objective on the stock. Zacks Investment Research raised Zymeworks from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a research note on Saturday, April 13th. ValuEngine downgraded Intersect ENT from a “buy” rating to a “hold” rating in a research note on Monday, June 3rd. Finally, BidaskClub downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 9th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and two have given a strong buy rating to the company’s stock. MarketAxess presently has an average rating of “Hold” and a consensus target price of $240.57.

In other MarketAxess news, CEO Richard M. Mcvey sold 20,000 shares of the stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $281.14, for a total transaction of $5,622,800.00. Following the completion of the transaction, the chief executive officer now owns 1,006,289 shares in the company, valued at approximately $282,908,089.46. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Stephen P. Casper sold 102 shares of the stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $337.30, for a total value of $34,404.60. Following the transaction, the director now owns 13,157 shares of the company’s stock, valued at approximately $4,437,856.10. The disclosure for this sale can be found here. In the last quarter, insiders have sold 27,591 shares of company stock valued at $7,719,158. Corporate insiders own 3.28% of the company’s stock.

About MarketAxess

MarketAxess Holdings Inc, together with its subsidiaries, operates an electronic trading platform that enables fixed-income market participants to trade corporate bonds and other types of fixed-income instruments worldwide. It offers institutional investor and broker-dealer firms the access to global liquidity in U.S.

Featured Story: What is the Dividend Aristocrat Index?

Earnings History for MarketAxess (NASDAQ:MKTX)

Receive News & Ratings for MarketAxess Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MarketAxess and related companies with's FREE daily email newsletter.